With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.25637-18-7,4-Iodotetrahydro-2H-pyran,as a common compound, the synthetic route is as follows.
NEt3 (1. 3mL, 9. 0MMOL) and 4-iodotetrahydropyran (1.93g, 9. 0MMOL) were added to a stirred solution of ethyl (4-MERCAPTOPHENYL) acetate (1. 21g, 6. 0mmol) in anhydrous DMF (LOML) at 0 C. The mixture was allowed to warm to room temperature over 3d, then the solvents were removed under reduced pressure. The residue was partitioned between Et20 (LOOML) and saturated aqueous NH4CL (50ML), the aqueous phase being extracted further with ET20 (45mL). The combined ethereal extracts were washed with H20 (50ML), H20-SATURATED aqueous NA2C03 (1: 1, 50ML), and brine (50ML), before being dried (MGS04). Filtration, solvent evaporation, and flash chromatography (IH-ET20, 10: 1 to 2: 1) afforded the title compound: RF (IH-ET20, 2: 1) =0. 31.
25637-18-7, The synthetic route of 25637-18-7 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; OSI PHARMACEUTICALS, INC.; WO2004/72031; (2004); A2;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics